Other equities research analysts have also recently issued reports about the stock. Analysts at JMP Securities upgraded shares of Insmed Incorporated from a “market perform” rating to an “outperform” rating in a research note on Thursday, January 9th. They now have a $25.00 price target on the stock. Separately, analysts at UBS AG reiterated a “buy” rating on shares of Insmed Incorporated in a research note on Monday, January 6th. They now have a $31.00 price target on the stock, up previously from $17.50. Finally, analysts at Piper Jaffray initiated coverage on shares of Insmed Incorporated in a research note on Tuesday, November 26th. They set an “overweight” rating and a $34.00 price target on the stock. Two analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $23.00.
Note the claim "Two analysts have rated stock with a sell rating", but only Wedbush is named. JMP, UBS, and Piper are acknowledged to be in the "buy" camp. Is there a second "sell" analyst, or was the editor careless in re-writing this piece?